Leyden Labs Targets Viral Families To Head Off Next Pandemic
Start-Up Developing Novel Intranasal Medicine
Emerging Company Profile: While vaccines target specific viruses, Dutch start-up Leyden Labs is hunting down commonalities in viral families and working on the delivery of intranasal molecules that can protect humans from both known and future viruses.
You may also be interested in...
Ipsen has inked a worldwide collaboration pact with BAKX Therapeutics to research, develop, manufacture and commercialize the biotech’s asset BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.
A surprise surge in Roche's R&D spending this year reflects high quality in-house innovation opportunities as well as high prices for external M&A targets, management said.
Roche unveiled a strong Q2 performance driven by new medicines and continued strong growth from its diagnostics division but analysts were most keen for clues on plans for gantenerumab, now in Phase III studies for Alzheimer’s disease.